Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Canadian Study of Arterial Inflammation in Diabetes and the Evaluation of Canakinumab Effectiveness (CADENCE)

FY 2018-19

Summary
Diabetic patients are at very high risk of suffering premature atherosclerotic disease related events (eg acute coronary syndromes (ACS), stroke, transient ischemic attacks (TIAs)) and have a higher recurrence rate than the general population. Inflammation has been extensively investigated as a promoter of atherosclerosis development and destabilization. Very recently the CANTOS trial demonstrated that therapy focused at blocking the inflammatory cascade reduced recurrent events in patients with prior acute coronary syndromes. Canakinumab treatment was particularly effective in patients who achieved a significant hsCRP reduction, but was associated with a significant increase in fatal sepsis, with no impact on de-novo diabetes mellitus or worsening of diabetes control. This is important since approximately 40% of the patients enrolled in the CANTOS trial were patients with diabetes. The results from CANTOS raise an intriguing question of how to identify the patients who will benefit the most from this innovative therapy. Investigators in the field of imaging have been investigating means to identify patients at greater risk of suffering events who would benefit from specific therapeutic interventions. PET-CT provides an opportunity to perform molecular imaging of specific components of the atherosclerotic plaque such as inflammation. 18FDG has been validated and extensively used for this purpose, and it could potentially enable the prospective evaluation of inflammation-targeted therapies and the identification of patients at high-risk for vascular events. Simultaneous blood biomarker analysis can provide potential screening candidates calibrated to the response on the 18FDG scan to facilitate future screening of patients suitable for evaluation.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406423
Name
Boczar Kevin E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canadian Study of Arterial Inflammation in Diabetes and the Evaluation of Canakinumab Effectiveness (CADENCE)
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Canakinumab; Cardiology; Coronary Artery Disease; Imaging; Myocardial Infarction; Pet Imaging; Stroke
Abstract
Diabetic patients are at very high risk of suffering premature atherosclerotic disease related events (eg acute coronary syndromes (ACS), stroke, transient ischemic attacks (TIAs)) and have a higher recurrence rate than the general population. Inflammation has been extensively investigated as a promoter of atherosclerosis development and destabilization. Very recently the CANTOS trial demonstrated that therapy focused at blocking the inflammatory cascade reduced recurrent events in patients with prior acute coronary syndromes. Canakinumab treatment was particularly effective in patients who achieved a significant hsCRP reduction, but was associated with a significant increase in fatal sepsis, with no impact on de-novo diabetes mellitus or worsening of diabetes control. This is important since approximately 40% of the patients enrolled in the CANTOS trial were patients with diabetes. The results from CANTOS raise an intriguing question of how to identify the patients who will benefit the most from this innovative therapy. Investigators in the field of imaging have been investigating means to identify patients at greater risk of suffering events who would benefit from specific therapeutic interventions. PET-CT provides an opportunity to perform molecular imaging of specific components of the atherosclerotic plaque such as inflammation. 18FDG has been validated and extensively used for this purpose, and it could potentially enable the prospective evaluation of inflammation-targeted therapies and the identification of patients at high-risk for vascular events. Simultaneous blood biomarker analysis can provide potential screening candidates calibrated to the response on the 18FDG scan to facilitate future screening of patients suitable for evaluation.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boczar, Kevin E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~